Intradialytic clearance of opioids: Methadone versus hydromorphone

Pain

Volumn 154, Issue 12, 2013, Pages 2794-2800

  Perlman, Ryan ^a,b   Giladi, Hili ^a   Brecht, Krista ^a   Ware, Mark A ^a   Hebert, Terence E ^c   Joseph, Lawrence ^c   Shir, Yoram ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Chronic pain; Dialysis; Hydromorphone; Methadone; Pharmacokinetics

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC PAIN; DIALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG POTENCY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PAIN ASSESSMENT; PLASMA CLEARANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION;

CHRONIC PAIN; DIALYSIS; HYDROMORPHONE; METHADONE; PHARMACOKINETICS;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROMORPHONE; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; METHADONE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84889086848     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.08.015     Document Type: Article

References (49)

1. M.S. Angst, M. Buhrer, and J. Lotsch Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucoronide action Anesthesiology 92 2000 1473 1476
2. N. Babul, A.C. Darke, and N. Hagen Hydromorphone metabolite accumulation in renal failure [letter] J Pain Symptom Manage 10 1995 184 186
3. B. Bastani, and J.A. Jamal Removal of morphine but not fentanyl during haemodialysis [letter] Nephrol Dial Transplant 12 1997 2804
4. R. Bellomo, C. Ronco, J.A. Kellum, R.L. Mehta, and R. Palevsky Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group Crit Care 8 2004 204 212
5. V.T. Chang, S.S. Hwang, and M. Feuerman Validation of the edmonton symptom assessment scale Cancer 88 2000 2164 2171
6. J.M. Corkery, F. Schifano, A.H. Ghodse, and A. Oyefeso The effects of methadone and its role in fatalities Hum Psychopharmacol 19 2004 565 576
7. D.I. Cubero, and A. del Giglio Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study Support Care Cancer 18 2010 235 242
8. G. Davies, C. Kingswood, and M. Street Pharmacokinetics of opioids in renal dysfunction Clin Pharmacokinet 31 1996 410 422
9. S.N. Davison Pain in hemodialysis patients: prevalence, cause, severity and management Am J Kidney Dis 42 2003 1239 1247
10. S.N. Davison, and P.R. Mayo Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients J Opioid Manag 4 2008 335 344
11. M. Dean Opioids in renal failure and dialysis patients J Pain Symptom Manage 28 2004 497 504
12. T.A. Depner Hemodialysis adequacy. Basic essentials and practical points for the nephrologists in training Hemodial Int 9 2005 241 254
13. J.A. Diaz-Buxo, E.G. Lowrie, N.L. Lew, H. Zhang, and J.M. Lazarus Quality-of-life evaluation using the Short-Form 36. Comparison in hemodialysis and peritoneal dialysis patients Am J Kidney Dis 35 2000 293 300
14. C. Durnin, I.D. Hind, M.M. Wickens, D.B. Yates, and K.-H. Molz Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment Proc West Pharmacol Soc 44 2001 81 82
15. C.B. Eap, T. Buclin, and P. Baumann Interindividual variability of the clinical pharmacokinetics of methadone - implications for the treatment of opioid dependence Clin Pharmacokinet 41 2002 1153 1193
16. A. Ferrari, C.P. Coccia, A. Bertolini, and E. Sternieri Methadone - metabolism, pharmacokinetics and interactions Pharmacol Res 50 2004 551 559
17. F. Fortina, S. Agllata, E. Ragazzoni, A. Sacco, V. Cardillo, S. Travaglini, P. Brini, and A. Cavagnino Chronic pain during dialysis. Pharmacologic therapy and its costs Minerva Urol Nefrol 51 1999 85 87
18. V. Furlan, A. Hafi, M.C. Dessalles, J. Bouchez, B. Charpentier, and A.M. Taburet Methadone is poorly removed by haemodialysis Nephrol Dial Transplant 14 1999 254
19. B. Gagnon, A. Almahrezi, and G. Schreier Methadone in the treatment of neuropathic pain Pain Res Manage 8 1999 149 154
20. J.S. Gardner-Nix Oral methadone for managing chronic nonmalignant pain J Pain Symptom Manage 11 1996 321 328
21. M.J. Garrido, and I.F. Troconiz Methadone: a review of its pharmacokinetic and pharmacodynamic properties J Pharmacol Toxicol Methods 42 1999 61 66
22. W.M. Glazer, and G.L. Cohn Methadone maintenance in a patient on chronic hemodialysis Am J Psychiatry 134 1977 931 932
23. G.K. Gourlay, D.A. Cherry, and M.J. Cousins A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer PAIN® 25 1986 297 312
24. D.R.P. Guay, W.M. Awni, J.W. Findlay, C.E. Halstenson, P.A. Abraham, J.A. Opsahl, E.C. Jones, and G.R. Matzke Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease Clin Pharmacol Ther 43 1988 63 71
25. M.H. Hanna, F. D'Costa, S.J. Peat, C. Fung, N. Venkat, T.R. Zilkha, and S. Davies Morphine-6-glucuronide disposition in renal impairment Br J Anaesth 70 1993 511 514
26. H. Hays, and M.A. Woodroffe Use of methadone in treating chronic noncancer pain Pain Res Manage 4 1999 23 27
27. J. Joh, M.K. Sila, and B. Bastani Nondialyzability of fentanyl with high-efficiency and high-flux membranes [letter] Anesth Analg 86 1998 447
28. M.J. Kreek, A.J. Schecter, C.L. Gutjahr, and M. Hecht Methadone use in patients with chronic renal disease Drug Alcohol Depend 5 1980 197 205
29. B.M. Kuehn Methadone overdose deaths rise with increased prescribing for pain JAMA 308 2012 749 750
30. S. Mercadante, M. Sapio, R. Serretta, and M. Caligara Patient-controlled analgesia with oral methadone in cancer pain: preliminary report Ann Oncol 7 1996 613 617
31. A. Murray, and N.A. Hagen Hydromorphone J Pain Symptom Manage 29 2005 57 66
32. D.M. Novick, M.J. Kreek, A.M. Fanizza, S.R. Yancovitz, A.M. Gelb, and R.J. Stenger Methadone disposition in patients with chronic liver disease Clin Pharmacol Ther 30 1981 353 362
33. D.M. Novick, M.J. Kreek, P.A. Arns, L.L. Lau, S.R. Yancovitz, and A.M. Gelb Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients Alcohol Clin Exp Res 9 1985 349 354
34. R.J. Osborne, S.P. Joel, and M.L. Slevin Morphine intoxication in renal failure: the role of morphine-6-glucuronide Br Med J 292 1986 1548 1549
35. P.V. Parab, W.A. Ritschel, D.E. Coyle, R.V. Gregg, and D.D. Denson Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects Biopharm Drug Dispos 9 1988 187 199
36. P. Parker, and W. Parker Pharmacokinetic considerations in the hemodialysis of drugs J Clin Hosp Pharm 7 1982 8749
37. R.K. Portenoy, and K.M. Foley Chronic use of opioid analgesics in non-malignant pain: report of 38 cases PAIN® 25 1986 171 186
38. D.D. Price, P.A. McGrath, A. Rafii, and B. Buckingham The validation of visual analogue scales as ratio scale measures for chronic and experimental pain PAIN® 17 1983 45 56
39. M.M. Reidenberg, H. Goodman, H. Erie, G. Gray, B. Lorenzo, R.M. Leipzig, B.R. Meyer, and D.E. Drayer Hydromorphone levels and pain control in patients with severe chronic pain Clin Pharmacol Ther 44 1988 376 382
40. Y. Shir, Z. Shenkman, V. Shavelson, E.M. Davidson, and G. Rosen Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases Clin J Pain 14 1998 350 353
41. Y. Shir, G. Rosen, A. Zeldin, and E.M. Davidson Methadone is safe for treating hospitalized patients with severe pain Can J Anaesth 48 2001 1109 1113
42. M.A. Tortorici, D. Cutler, L. Zhang, and M. Pfister Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function J Clin Pharmacol 52 2012 109 118
43. A. Trescot, S. Datta, M. Lee, and H. Hansen Opioid pharmacology Pain Physician 11 2008 133 153
44. Treatment of End-Stage Organ Failure in Canada 1999-2008. Annual Report, Canadian Organ Replacement Register; 2010.
45. N. Sarhill, D. Walsh, and K.A. Nelson Hydromorphone: pharmacology and clinical applications in cancer patients Support Care Cancer 9 2001 84 96
46. D. Thwaites, S. McCann, and P. Broderick Hydromorphone neuroexcitation J Palliat Med 7 2004 545 550
47. J.J. Vallner, J.T. Stewart, J.A. Kotzan, E.B. Kirsten, and I.L. Honigberg Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects J Clin Pharmacol 4 1981 152 156
48. J. Ware Jr, M. Kosinski, and S.D. Keller A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
49. A.W. Wright, L.E. Mather, and M.T. Smith Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide Life Sci 69 2001 409 420